Playback speed
10 seconds
Has the KEYNOTE-189 Trial Defined a Clear Standard of Care in Metastatic NSCLC?
By
Beacon Medical Interchange
FEATURING
Jack West
By
Beacon Medical Interchange
FEATURING
Jack West
20 views
November 2, 2018
Dr. Jack West reviews the results and pending questions of the KEYNOTE-189 trial of chemotherapy ...
read more ↘ with or without pembrolizumab (KEYTRUDA) as first line therapy for advanced non-squamous NSCLC, as well as how they change the treatment landscape.
↖ read less
read more ↘ with or without pembrolizumab (KEYTRUDA) as first line therapy for advanced non-squamous NSCLC, as well as how they change the treatment landscape.
↖ read less
Comments 0
Login to view comments.
Click here to Login
Lung